Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Control Governance: Regulatory Bodies and Their Impact

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oncology Drugs: The Authors Reply.

Health affairs (Project Hope)·2025

Same author

Assessing the Value of Integrated Evidence Approaches in Drug Development.

Therapeutic innovation & regulatory science·2025

Same author

Postapproval Innovation For Oncology Drugs And The Inflation Reduction Act.

Health affairs (Project Hope)·2024

Same author

Assessing the net financial benefits of employing digital endpoints in clinical trials.

Clinical and translational science·2024

Same author

New Estimates on the Cost of a Delay Day in Drug Development.

Therapeutic innovation & regulatory science·2024

Same author

Impact of regulatory system changes on the availability of innovative drugs in China.

Nature reviews. Drug discovery·2023

Same journal

Still Learning from Oregonians About Medicaid.

Journal of health politics, policy and law·2026

Same journal

Communicative Infrastructure and the Global Diffusion of Latin American Food Policy.

Journal of health politics, policy and law·2026

Same journal

Frankenstein or My Fair Lady? Lessons on Participatory Governance from Oregon Medicaid's Priority-Setting Experiment.

Journal of health politics, policy and law·2026

Same journal

How Medicare Advantage Enrollment Affects Spending in Traditional Medicare: Spillovers and Implications for MA Benchmarks.

Journal of health politics, policy and law·2026

Same journal

Abortion Politics: Physician Mobilization in the Wake of the Dobbs Decision.

Journal of health politics, policy and law·2026

Same journal

When Protections Work but Processes Stall: Evaluating the No Surprises Act's Implementation Record.

Journal of health politics, policy and law·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Misleading congress about drug development: Reply.

Joseph A Dimasi¹, Ronald W Hansen, Henry G Grabowski

¹Tufts University.

Journal of Health Politics, Policy and Law

|March 8, 2008

Summary

This summary is machine-generated.

This analysis addresses factual errors and flawed conclusions in a review of pharmaceutical research and development (R&D) economics. It highlights omissions regarding industry cost studies and rebuttal responses.

More Related Videos

Comprehensive Analysis of Drug Response using the FLICK Assay

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jul 6, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Comprehensive Analysis of Drug Response using the FLICK Assay

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

Area of Science:

Health Economics
Pharmaceutical Policy
Biotechnology Industry Analysis

Background:

A review essay by Donald Light critiqued a Congressional Budget Office report on pharmaceutical research and development (R&D).
The review essay contained alleged factual inaccuracies and omissions.
Concerns were raised about the handling of criticisms regarding R&D cost studies and industry economics.

Purpose of the Study:

To identify and correct factual errors in Donald Light's review essay.
To provide a comprehensive overview of rebuttal responses to criticisms of R&D cost studies.
To offer accurate conclusions regarding the economics of the pharmaceutical industry.

Main Methods:

Critical analysis of the review essay by Donald Light.
Examination of the Congressional Budget Office report and related R&D cost studies.
Review of available rebuttal literature addressing criticisms of pharmaceutical R&D economics.

Main Results:

The review essay contains demonstrable factual errors.
The essay fails to inform readers about crucial rebuttal responses to critiques of R&D cost studies.
Erroneous conclusions were drawn regarding the fundamental nature of pharmaceutical industry economics.

Conclusions:

Donald Light's review essay presents a mischaracterization of pharmaceutical R&D economics.
Accurate assessment requires addressing factual errors and considering all relevant rebuttal data.
Further research should ensure comprehensive and unbiased analysis of industry economic models.